Thế Giới

UK approves Evosheld antibody therapy for COVID-19 prophylaxis

AstraZeneca’s Evusheld. (Photo: Evening Standard)

The decision was made by the UK Medicines and Healthcare products Regulatory Agency (MHRA) after the British Government’s Scientific Advisory Council assessed the evidence on the effectiveness of the drug. Eveld. This is monoclonal antibodies The first in the world to be licensed to produce prophylactic treatment for COVID-19.

AstraZeneca’s Evusheld monoclonal antibody mixture is considered a new hope against the COVID-19 epidemic when it has an immediate effect, directly providing antibodies that provide protection within a few hours after injection. Test results show that Evusheld has the ability to prevent symptoms by up to 77% with a protective effect within 6 months after only one dose, which is considered superior to vulnerable subjects. by the SARS-CoV-2 virus.

In December 2021, AstraZeneca said that Evusheld was effective in neutralizing the Omicron variant, but in the new MHRA announcement, more data is still needed to conclude whether this drug works with the Omicron variant. no, or how long the drug worked before this variant.

UK approves Evosheld antibody therapy for COVID-19 prophylaxis - Photo 1.

Evusheld is indicated for pre-exposure prophylaxis to SARS-CoV-2. (Photo: AP)

Evusheld was developed from a mixture of two monoclonal antibodies tixagevimab and cilgavimab to prevent COVID-19 and prevent severe disease progression in high-risk groups such as immunocompromised, unable to produce antibodies despite injections. full dose of vaccine, or who are unable to receive the vaccine.

Unlike most other COVID-19 treatments, which are given to hospitalized patients to prevent serious complications from the disease, Evosheld is the only monoclonal antibody drug currently available for parenteral use. corn and is indicated for pre-exposure prophylaxis to SARS-CoV-2.

Evusheld is currently approved for use in the United States to prevent disease in people with weakened immune systems or a history of serious side effects after receiving the COVID-19 vaccine. In Vietnam, Evusheld has also been granted a special import license by the Ministry of Health to meet the needs of COVID-19 prevention for high-risk subjects, people with underlying diseases, immunocompromised or unvaccinated people. vaccine against COVID-19

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!

You are reading the article UK approves Evosheld antibody therapy for COVID-19 prophylaxis
at – Source: – Read the original article here

Back to top button